Daxor (DXR) Forward Dividend Yield % : 0.00% (As of Apr. 30, 2024)

View and export this data going back to 1992. Start your Free Trial

What is Daxor Forward Dividend Yield %?

As of today (2024-04-30), the Forward Annual Dividend Yield of Daxor is 0.00%.

As of today (2024-04-30), the Trailing Annual Dividend Yield of Daxor is 0.00%.

DXR's Forward Dividend Yield % is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 1.93
* Ranked among companies with meaningful Forward Dividend Yield % only.

Daxor's Dividends per Share for the six months ended in Dec. 2023 was $0.00.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Daxor was -15.70% per year. The lowest was -68.90% per year. And the median was -45.70% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Daxor's Forward Dividend Yield %

For the Medical Instruments & Supplies subindustry, Daxor's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daxor's Forward Dividend Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Daxor's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Daxor's Forward Dividend Yield % falls into.

Daxor Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Daxor (NAS:DXR) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Daxor Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Daxor's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Daxor (DXR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

DX5:Germany

Address

109 Meco Lane, Oak Ridge, TN, USA, 37830

Website

https://www.daxor.com

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Executives

Robert J Michel	officer: CHIEF FINANCIAL OFFICER	C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Michael Richard Feldschuh	director	71 GRAND STREET #2, NEW YORK NY 10013
Joy S. Goudie	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers	director	DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Edward Feuer	director	2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Soren Thompson	officer: V.P./BUSINESS DEVELOPMENT	180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh	director, officer: CHIEF SCIENTIFIC OFFICER	DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh	officer: President	615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh	other: FOUNDER	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan	officer: Corporate Secretary	259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe	director	6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens	director	200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson	director	P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom	officer: Vice President	3244 BLACK FOX ROAD, WASHBURN TN 37888